Bio shares ready to recover on growing investment, eased regulations
Sept 2, 2018
Shrugging off concerns over overvaluation and uncertainties regarding accounting regulations, South Korea's pharmaceutical and bio companies have shown signs of regaining their presence on the stock market.On Friday, Samsung BioLogics, a biopharmaceutical affiliate of the country's largest conglomerate, Samsung, spiked 3.7 percent to end at 463,000 won ($415.66). Celltrion also surged 1.31 percent to 270,000 won, and Hanmi Pharmaceutical grew 1.84 percent to 497,500 won. The upturn came af